Tarsus Pharmaceuticals
TARS
220 hedge funds and large institutions have $2.67B invested in Tarsus Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 66 increasing their positions, 93 reducing their positions, and 22 closing their positions.
179% more call options, than puts
Call options by funds: $3.14M | Put options by funds: $1.13M
68% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 22
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
43% more capital invested
Capital invested by funds: $1.87B → $2.67B (+$799M)
7% more funds holding
Funds holding: 205 → 220 (+15)
3.45% less ownership
Funds ownership: 109.8% → 106.35% (-3.5%)
29% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 93
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$61.5M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$19.2M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$13.2M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$12.3M |
| 5 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$22M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$18.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$18.1M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$15.8M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$15.3M |
TARS Hedge Fund Activity: Q3 2025 in Review
220 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q3 2025, worth a combined $2.67B — up 43% from $1.87B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new TARS positions and 22 closed out — a net gain of 15 holders — while 66 added to existing stakes and 93 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $61.5M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $22M sold.
- 220 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q3 2025, up from 205 in Q2 2025.
- Funds reported $2.67B of Tarsus Pharmaceuticals stock for Q3 2025, up 43% quarter-over-quarter.
- 37 funds opened new Tarsus Pharmaceuticals positions in Q3 2025 and 22 closed out, a net change of +15 holders.
- The largest Tarsus Pharmaceuticals buyer in Q3 2025 was Deep Track Capital, an estimated $61.5M added.
- The largest Tarsus Pharmaceuticals seller in Q3 2025 was Adage Capital Partners, an estimated $22M sold.
Based on aggregated 13F filings for Q3 2025.